- $546.63m
- $404.45m
- $418.63m
Brief: MiMedx Announces Fourth Quarter And Full Year 2021 Operating And Financial Results
MiMedx Group Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: MiMedx Announces Dismissal Of Putative Securities Class Action Lawsuit
Brief: MiMedx Group Inc Increases 2021 Adjusted Net Sales Outlook To Between $253 Mln And $258 Mln
U.S. STOCKS ON THE MOVE-Macy's, Netflix, Pfizer
U.S. STOCKS ON THE MOVE-Netflix, Chevron, American Airlines
Brief: Peer Reviewed Study Demonstrates MIMEDX's PURION® Processed Placental Allografts Outperforms Standard of Care in Select Mohs Defect Reconstructions
Brief: MiMedx Announces Q3 2021 Operating And Financial Results
MiMedx Group Inc expected to post a loss of 8 cents a share - Earnings Preview
MiMedx plunges after two movement disorder trials fail to meet main goals
U.S. STOCKS ON THE MOVE-Aterian, Farmmi, Moderna
U.S. STOCKS ON THE MOVE-Porch Group, Apple, Genworth Financial
U.S. STOCKS ON THE MOVE-Virgin Galactic, Alibaba, Avantor
Brief: Mimedx Reports Top-Line Data From Two Late-Stage Musculoskeletal Trials With Proprietary Amniotic Tissue Technology
Brief: MiMedx Announces Effectiveness Of Shelf Registration Statement
Brief: MiMedx Group Inc Files For Mixed Shelf Of Up To $350 Mln
Brief: MIMEDX Promotes Marion Snyder To Chief Of Staff, Senior Vice President, Government Affairs
MiMedx Group Inc reports results for the quarter ended in June - Earnings Summary
Brief: MiMedx Reports Q2 Sales Of $68.2 Mln